Advertisement

18F-Labeled Radiotracers for Prostate-specific Membrane Antigen

Historical Perspective and Future Directions
  • Steven P. Rowe
    Correspondence
    Corresponding author. Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street JHOC Room 3233, Baltimore, MD 21287.
    Affiliations
    The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA

    The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA
    Search for articles by this author
  • Ali Salavati
    Affiliations
    The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA
    Search for articles by this author
  • Rudolf A. Werner
    Affiliations
    The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA

    Department of Nuclear Medicine, Wuerzburg University Hospital, Oberduerrbacher Street 6, 97080 Wuerzburg, Germany
    Search for articles by this author
  • Kenneth J. Pienta
    Affiliations
    The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA
    Search for articles by this author
  • Michael A. Gorin
    Affiliations
    Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1272, New York, NY 10029, USA
    Search for articles by this author
  • Martin G. Pomper
    Affiliations
    The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA

    The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA
    Search for articles by this author
  • Lilja B. Solnes
    Affiliations
    The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to PET Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rowe S.P.
        • Pomper M.G.
        Molecular imaging in oncology: current impact and future directions.
        CA Cancer J Clin. 2021; 72: 333-352
        • Rowe S.P.
        • Gorin M.A.
        • Pomper M.G.
        Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications.
        Annu Rev Med. 2019; 70: 461-477
        • Perera M.
        • Papa N.
        • Christidis D.
        • et al.
        Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis.
        Eur Urol. 2016; 70: 926-937
        • Sanchez-Crespo A.
        Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography.
        Appl Radiat Isot. 2013; 76: 55-62
        • Gorin M.A.
        • Pomper M.G.
        • Rowe S.P.
        PSMA-targeted imaging of prostate cancer: the best is yet to come.
        BJU Int. 2016; 117: 715-716
        • Rowe S.P.
        • Gorin M.A.
        • Salas Fragomeni R.A.
        • et al.
        Clinical experience with 18F-labeled small molecular inhibitors of prostate-specific membrane antigen.
        PET Clin. 2017; 12: 235-241
        • Werner R.A.
        • Derlin T.
        • Lapa C.
        • et al.
        18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging.
        Theranostics. 2020; 10: 1-16
        • Pomper M.G.
        • Musachio J.L.
        • Zhang J.
        • et al.
        11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase).
        Mol Imaging. 2002; 1: 96-101
        • Rowe S.P.
        • Drzezga A.
        • Neumaier B.
        • et al.
        Prostate-specific membrane antigen-targeted radiohalogenated PET and therapeutic agents for prostate cancer.
        J Nucl Med. 2016; 57: 90S-96S
        • Guilarte T.R.
        • McGlothan J.L.
        • Foss C.A.
        • et al.
        Glutamate carboxypeptidase II levels in rodent brain [125I]DCIT quantitative autoradiography.
        Neurosci Lett. 2005; 387: 141-144
        • Mease R.C.
        • Dusich C.L.
        • Foss C.A.
        • et al.
        N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer.
        Clin Cancer Res. 2008; 14: 3036-3043
        • Banerjee S.R.
        • Pullambhatla M.
        • Byun T.
        • et al.
        68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.
        J Med Chem. 2010; 53: 5333-5341
        • Cho S.Y.
        • Gage K.L.
        • Mease R.C.
        • et al.
        Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
        J Nucl Med. 2012; 53: 1883-1891
        • Rowe S.P.
        • Macura K.J.
        • Ciarallo A.
        • et al.
        Comparison of prostate-specific membrane antigen-based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naïve and castration-resistant metastatic prostate cancer.
        J Nucl Med. 2016; 57: 46-53
        • Rowe S.P.
        • Gage K.L.
        • Faraj S.F.
        • et al.
        18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer.
        J Nucl Med. 2015; 56: 1003-1010
        • Lesche R.
        • Kettschau G.
        • Gromov A.V.
        • et al.
        Preclinical evaluation of BAY 1075553, a novel 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer.
        Eur J Nucl Med Mol Imaging. 2014; 41: 89-101
        • Beheshti M.
        • Kunit T.
        • Haim S.
        • et al.
        BAY 1075553 PET-CT for staging and restaging prostate cancer patients: comparison with [18F] fluorocholine PET-CT (phase I study).
        Mol Imaging Biol. 2015; 17: 424-433
        • Rowe S.P.
        • Buck A.
        • Bundschuh R.A.
        • et al.
        [18F]DCFPyL PET/CT for imaging of prostate cancer.
        Nuklearmedizin. 2022; 61: 240-246
        • Szabo Z.
        • Mena E.
        • Rowe S.P.
        • et al.
        Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer.
        Mol Imaging Biol. 2015; 17: 565-574
        • Rowe S.P.
        • Macura K.J.
        • Mena E.
        • et al.
        PSMA-based [18F]DCFPyL PET/CT is Superior to conventional imaging for lesion detection in patients with metastatic prostate cancer.
        Mol Imaging Biol. 2016; 18: 411-419
        • Gorin M.A.
        • Rowe S.P.
        • Patel H.D.
        Prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study.
        J Urol. 2018; 199: 126-132
        • Rowe S.P.
        • Campbell S.P.
        • Mana-Ay M.
        • et al.
        Prospective evaluation of PSMA-targeted 18F-DCFPyL PET/CT in men with biochemical failure after radical prostatectomy for prostate cancer.
        J Nucl Med. 2020; 61: 58-61
        • Markowski M.C.
        • Sedhom R.
        • Fu W.
        • et al.
        Prostate specific antigen and prostate specific antigen doubling time predict findings on 18 F-DCFPyL positron emission tomography/computerized tomography in patients with biochemically recurrent prostate cancer.
        J Urol. 2020; 204: 496-502
        • Mena E.
        • Rowe S.P.
        • Shih J.H.
        • et al.
        Predictors of 18F-DCFPyL-PET/CT positivity in patients with biochemical recurrence of prostate cancer after local therapy.
        J Nucl Med. 2021; 63: 1184-1190
        • Rowe S.P.
        • Li X.
        • Trock B.J.
        • et al.
        Prospective comparison of PET imaging with PSMA-targeted 18F-DCFPyL versus Na18F for bone lesion detection in patients with metastatic prostate cancer.
        J Nucl Med. 2020; 61: 183-188
        • Zukotynski K.A.
        • Emmenegger U.
        • Hotte S.
        • et al.
        Prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane antigen-targeted 18F-DCFPyL PET/CT in patients with castration-resistant prostate cancer Starting abiraterone or enzalutamide.
        J Nucl Med. 2021; 62: 1430-1437
        • Markowski M.C.
        • Velho P.I.
        • Eisenberger M.A.
        • et al.
        Detection of early progression with 18F-DCFPyL PET/CT in men with metastatic castration-resistant prostate cancer receiving bipolar androgen therapy.
        J Nucl Med. 2021; 62: 1270-1273
        • Cysouw M.C.F.
        • Jansen B.H.E.
        • Yaqub M.
        • et al.
        Letter to the Editor re: Semiquantitative parameters in PSMA-targeted PET imaging with [18F]DCFPyL: impact of tumor burden on normal organ uptake.
        Mol Imaging Biol. 2020; 22: 15-17
        • Li X.
        • Rowe S.P.
        • Leal J.P.
        • et al.
        Semiquantitative parameters in PSMA-targeted PET imaging with 18F-DCFPyL: variability in normal-organ uptake.
        J Nucl Med. 2017; 58: 942-946
        • Sahakyan K.
        • Li X.
        • Lodge M.A.
        • et al.
        Semiquantitative parameters in PSMA-targeted PET imaging with [18F]DCFPyL: intrapatient and interpatient variability of normal organ uptake.
        Mol Imaging Biol. 2020; 22: 181-189
        • Werner R.A.
        • Bundschuh R.A.
        • Bundschuh L.
        • et al.
        Semiquantitative parameters in PSMA-targeted PET imaging with [18F]DCFPyL: impact of tumor burden on normal organ uptake.
        Mol Imaging Biol. 2020; 22: 190-197
        • Pienta K.J.
        • Gorin M.A.
        • Rowe S.P.
        • et al.
        A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY).
        J Urol. 2021; 206: 52-61
        • Hope T.A.
        • Eiber M.
        • Armstrong W.R.
        • et al.
        Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial.
        JAMA Oncol. 2021; 7: 1635-1642
        • Morris M.J.
        • Rowe S.P.
        • Gorin M.A.
        • et al.
        Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study.
        Clin Cancer Res. 2021; 27: 3674-3682
        • Giesel F.L.
        • Cardinale J.
        • Schäfer M.
        • et al.
        18F-labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617.
        Eur J Nucl Med Mol Imaging. 2016; 43: 1929-1930
        • Giesel F.L.
        • Will L.
        • Lawal I.
        • et al.
        Intraindividual comparison of 18 F-PSMA-1007 and 18 F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study.
        J Nucl Med. 2018; 59: 1076-1080
        • Rauscher I.
        • Krönke M.
        • König M.
        • et al.
        Matched-pair comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy.
        J Nucl Med. 2020; 61: 51-57
        • Wondergem M.
        • van der Zant F.M.
        • Broos W.A.M.
        • et al.
        Matched-pair comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 prostate cancer patients: interreader agreement and lesion detection rate of suspected lesions.
        J Nucl Med. 2021; 62: 1422-1429
        • Malaspina S.
        • Anttinen M.
        • Taimen P.
        • et al.
        Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer.
        Eur J Nucl Med Mol Imaging. 2021; 48: 2951-2959
        • Ferrari M.
        • Treglia G.
        18F-PSMA-1007 PET in biochemical recurrent prostate cancer: an updated meta-analysis.
        Contrast Media Mol Imaging. 2021; 2021: 3502389
        • Wurzer A.
        • Di Carlo D.
        • Schmidt A.
        • et al.
        Radiohybrid ligands: a novel tracer concept Exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors.
        J Nucl Med. 2020; 61: 735-742
        • Kroenke M.
        • Wurzer A.
        • Schwamborn K.
        • et al.
        Histologically confirmed diagnostic efficacy of 18F-rhPSMA-7 PET for N-staging of patients with primary high-risk prostate cancer.
        J Nucl Med. 2020; 61: 710-715
        • Rauscher I.
        • Karimzadeh A.
        • Schiller K.
        • et al.
        Detection efficacy of 18F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
        J Nucl Med. 2021; 62: 1719-1726
        • Lee I.
        • Lim I.
        • Byun B.H.
        • et al.
        A microdose clinical trial to evaluate [ 18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer.
        Eur J Nucl Med Mol Imaging. 2021; 48: 95-102
        • Zlatopolskiy B.D.
        • Endepols H.
        • Krapf P.
        • et al.
        Discovery of 18 F-JK-PSMA-7, a PET probe for the detection of small PSMA-positive lesions.
        J Nucl Med. 2019; 60: 817-823
        • Dietlein F.
        • Mueller P.
        • Kobe C.
        • et al.
        [18F]-JK-PSMA-7 PET/CT under androgen deprivation therapy in advanced prostate cancer.
        Mol Imaging Biol. 2021; 23: 277-286
        • Behr S.C.
        • Aggarwal R.
        • VanBrocklin H.F.
        • et al.
        Phase I study of CTT1057, an 18 F-labeled imaging agent with phosphoramidate core targeting prostate-specific membrane antigen in prostate cancer.
        J Nucl Med. 2019; 60: 910-916
        • Phillips R.
        • Shi W.Y.
        • Deek M.
        • et al.
        Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial.
        JAMA Oncol. 2020; 6: 650-659
        • Schöder H.
        • Hope T.A.
        • Knopp M.
        • et al.
        Considerations on integrating prostate-specific membrane antigen positron emission tomography imaging into clinical prostate cancer trials by National clinical trials Network cooperative groups.
        J Clin Oncol. 2022; 40: 1500-1505
        • Murphy D.G.
        • Sweeney C.J.
        • Tombal B.
        Gotta catch 'em all", or do we? Pokemet approach to metastatic prostate cancer.
        Eur Urol. 2017; 72: 1-3
        • Froelich J.W.
        • Salavati A.
        Artificial intelligence in PET/CT is about to make whole-body tumor burden Measurements a clinical reality.
        Radiology. 2020; 294: 453-454
        • Rowe S.P.
        Artificial intelligence in molecular imaging: at the crossroads of revolutions in medical diagnosis.
        Ann Transl Med. 2021; 9: 817
        • Johnsson K.
        • Brynolfsson J.
        • Sahlstedt H.
        • et al.
        Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting.
        Eur J Nucl Med Mol Imaging. 2022; 49: 1041-1051